Bharat Biotech’s COVID-19 vaccine, Covaxin, will no longer have to carry the ‘clinical trial mode’ label. Serum Institute of India’s Covishield already has this status. Earlier, Covaxin was granted restricted emergency use authorisation before the completion of trials.
The government-backed vaccine has been developed by Bharat Biotech, a 24-year-old vaccine maker, which 16 vaccines to its name and exports to 123 countries. Addressing a weekly press conference on Thursday, NITI Aayog member (Health) Dr V K Paul said Covaxin has been granted permission for restricted use in an emergency situation in the public intrest.
- Amid unprecedented cases, Delhi govt converts 14 top private hospitals into COVID-only facilities - April 14, 2021
- UK expands COVID-19 vaccine programme to over-45s, UK PM urges caution - April 14, 2021
- COVID-19: Curfew in Maharashtra for 15 days from April 14, says CM Uddhav Thackeray - April 14, 2021
- Covid-19: India fast tracks vaccine imports, pricing unclear - April 14, 2021
- From dry mouth to hearing loss: Some lesser-known COVID symptoms to watch out for - April 14, 2021
- All women Lions club plans to set up a Charitable Clinic for Women and Children of Slum areas in Indiranagar in the city - April 12, 2021
- Go green with Mediterranean diet’s new form - April 12, 2021
- Shruti Seth opens up about nailing 3-minute headstand post laparoscopic surgery - April 12, 2021
- Safe Motherhood Day: How to prepare for a safe IVF pregnancy - April 12, 2021
- Vaccinated Indian national among 20 new COVID-19 cases reported in Singapore - April 12, 2021